UNC13A and amyotrophic lateral sclerosis: Data from 3 randomized trials on 518 participants showed that although lithium does not improve overall 12-month survival rate in the general ALS population, in UNC13A carriers, it increases the 12-month survival probability from 40.1% to 69.7% (van Eijk et al., 2017).